Bevacizumab for Advanced Breast Cancer

Women's Health

Volumn 6, Issue 1, 2010, Pages 17-25

  Goldfarb, Shari B ^a   Traina, Tiffany A ^a   Dickler, Maura N ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

advanced breast cancer; anti angiogenesis; Avastin ; bevacizumab; metastatic breast cancer; VEGF

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; MONOCLONAL ANTIBODY; TAXOID; VASCULOTROPIN A;

BREAST TUMOR; CLINICAL TRIAL; DISEASE COURSE; FEMALE; HUMAN; METASTASIS; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; REVIEW; STANDARD; TREATMENT OUTCOME;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; FEMALE; HUMANS; NEOPLASM METASTASIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TAXOIDS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77951236686     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/WHE.09.71     Document Type: Article

References (41)

1. Ferrara N: Role of vascular endothelial growth factor in the regulation of angiogenesis. Kidney Int. 56, 794–814 (1999).
2. Gasparini G. Angiogenesis in breast cancer: role in biology, tumor progression, and prognosis. In: Bowcock A (Ed.). Breast Cancer: Molecular Genetics, Pathogenesis, and Therapeutics. Humana Press, Inc., NJ, USA, 347–371 (1999).
3. Kerbel RS: Tumor Angiogenesis. N. Engl. J. Med. 358, 2039–2049 (2008).
4. Cross MJ Dixelius J Matsumoto T Claesson-Welsh L: VEGF-receptor signal transduction. Trends Biochem. Sci. 28, 488–494 (2003).
5. Foekens JA Peters HA Grebenchtchikov N et al.: High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res. 61, 5407–5414 (2001).
6. Linderholm B Tavelin B Grankvist K Henriksson R: Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma. J. Clin. Oncol. 16, 3121–3128 (1998).
7. Linderholm B Grankvist K Wilking N Johansson M Tavelin B Henriksson R: Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment. J. Clin. Oncol. 18, 1423–1431 (2000).
8. Presta LG Chen H O'Connor SJ et al.: Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 57, 4593–4599 (1997).
9. Kim KJ Li B Houck K Winer J Ferrara N: The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors 7, 53–64 (1992).
10. Gordon MS Margolin K Talpaz M et al.: Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J. Clin. Oncol. 19, 843–850 (2001).
11. Cobleigh MA Langmuir VK Sledge GW et al.: A Phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin. Oncol. 30, 117–124 (2003).
12. Miller KD Chap LI Holmes FA et al.: Randomized Phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J. Clin. Oncol. 23, 792–799 (2005).
13. Miller K Wang M Gralow J et al.: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med. 357, 2666–2676 (2007).
14. Klauber N Parangi S Flynn E Hamel E D'Amato RJ: Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res. 57, 81–86 (1997).
15. Miles D investigators A: A randomized, double-blind study of bevacizumab in combination with docetaxel as first-line treatment of patients with HER2-negative locally recurrent or metastatic breast cancer: efficacy and safety. J. Clin. Oncol. 26, LBA1011 (2008).
16. Wardley A Lohrisch C Joy AA et al.: Effect of anticoagulation therapy on bleeding and thromboembolic events in the AVADO Phase 3 study of docetaxel ± bevacizumab in metastatic or inoperable locally-recurrent breast cancer. Cancer Res. 69(Suppl. 2) 1035 (2009).
17. Dirix LY Romieu G Provencher L et al.: Safety of bevacizumab plus docetaxel in patients with locally-recurrent or metastatic breast cancer who developed brain metastases during the AVADO Phase 3 study. Cancer Res. 69(Suppl. 2) 4116 (2009).
18. Lobo CF Lopes G Silva O Gluck S: Nanoparticle albumin-bound (Nab) paclitaxel (P) in combination with bevacizumab (B) with and without gemcitabine (G): early experience at the Braman Family Breast Cancer Institute. J. Clin. Oncol. 2006 ASCO Annual Meeting Proceedings Part I 24 (2006).
19. Burstein H Parker L Savoie J: Phase II trial of the anti-VEGF antibody bevacizumab in combination with vinorelbine for refractory advanced breast cancer. Breast Cancer Res. Treat. 76 (2002).
20. Burstein H Spigel D Kindsvogel K et al.: Metronomic chemotherapy with and without bevacizumab for advanced breast cancer: a randomized Phase II study. Breast Cancer Res. Treat. 94(Suppl. 1) S6 (2005).
21. O'Shaughnessy JA Brufsky A: RiBBON 1 and RiBBON 2: Phase III Trials of bevacizumab with standard chemotherapy for metastatic breast cancer. Clin. Breast Cancer 8, 370–373 (2008).
22. Robert NJ Glaspy J Brufsky A et al.: RIBBON-1: randomized, double-blind, placebo-controlled, Phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC). J. Clin. Oncol. 27, S15 (2009) (Suppl. 15; J. 1005).
23. Ebos JM Lee CR Cruz-Munoz W Bjarnason GA Christensen JG Kerbel RS: Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15(3), 232–239 (2009).
24. Morales DE McGowan KA Grant DS et al.: Estrogen promotes angiogenic activity in human umbilical vein endothelial cells in vitro and in a murine model. Circulation 91, 755–763 (1995).
25. Losordo DW Isner JM: Estrogen and angiogenesis: a review. Arterioscler. Thromb. Vasc. Biol. 21, 6–12 (2001).
26. Kazi AA Jones JM Koos RD: Chromatin immunoprecipitation analysis of gene expression in the rat uterus in vivo: estrogen-induced recruitment of both estrogen receptor a and hypoxia-inducible factor 1 to the vascular endothelial growth factor promoter. Mol. Endocrinol. 19, 2006–2019 (2005).
27. Albrecht ED Aberdeen GW Niklaus AL Babischkin JS Suresch DL Pepe GJ: Acute temporal regulation of vascular endothelial growth/permeability factor expression and endothelial morphology in the baboon endometrium by ovarian steroids. J. Clin. Endocrinol. Metab. 88, 2844–2852 (2003).
28. Takei H Lee ES Jordan VC: In vitro regulation of vascular endothelial growth factor by estrogens and antiestrogens in estrogen-receptor positive breast cancer. Breast Cancer 9, 39–42 (2002).
29. Nakamura J Savinov A Lu Q Brodie A: Estrogen regulates vascular endothelial growth/permeability factor expression in 7,12-dimethylbenz(a)anthracene-induced rat mammary tumors. Endocrinology 137, 5589–5596 (1996).
30. Jain RK Safabakhsh N Sckell A et al.: Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor. Proc. Natl Acad. Sci. USA 95, 10820–10825 (1998).
31. Manders P Beex LV Tjan-Heijnen VC Span PN Sweep CG: Vascular endothelial growth factor is associated with the efficacy of endocrine therapy in patients with advanced breast carcinoma. Cancer 98, 2125–2132 (2003).
32. Traina T Dickler M Caravelli J et al.: A Phase II trial of letrozole in combination with bevacizumab, an anti-VEGF antibody, in patients with hormone receptor-positive metastatic breast cancer. Presented at: 28th Annual San Antonio Breast Cancer Symposium 2005. San Antonio, TX, USA, 8–11 December 2005.
33. Traina T Dickler M Caravelli J et al.: A feasibility study of an aromatase inhibitor, letrozole, and the antibody to vascular endothelial growth factor (VEGF), bevacizumab, in patients with hormone receptor-positive metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. 23, S76 (2005).
34. Traina TA Rugo HS Caravelli JF et al.: Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer. J. Clin. Oncol. 0:JCO.2009.21. 8784v1 (2009) (Epub ahead of print).
35. Yardley D Peacock N Arrowsmith E et al.: Preliminary safety results from a multicenter Phase 2 non-comparative two arm pilot of bevacizumab with anastrozole or fulvestrant as first-line metastatic breast cancer therapy. Cancer Res. 69(Suppl. 2) S2 (2009).
36. Pegram MD Reese DM: Combined biological therapy of breast cancer using monoclonal antibodies directed against HER2/neu protein and vascular endothelial growth factor. Semin. Oncol. 29, 29–37 (2002).
37. Linderholm B Andersson J Lindh B et al.: Overexpression of c-erbB-2 is related to a higher expression of vascular endothelial growth factor (VEGF) and constitutes an independent prognostic factor in primary node-positive breast cancer after adjuvant systemic treatment. Eur. J. Cancer 40(1), 33–34 (2004).
38. Epstein M Ayala R Tchekmedyian N Borgstrom P Pengram M Slamon D: HER2-overexpressing human breast cancer xenografts exhibit increased angiogenic potential mediated by vascular endothelial growth factor (VEGF). Breast Cancer Res. Treat. 76, S143 (2002).
39. Konecny GE Meng YG Untch M et al.: Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin. Cancer Res. 10, 1706–1716 (2004).
40. Pegram M Chan D Dichman RA et al.: Phase II combined biological therapy targeting the HER2 proto-oncogene and the vascular endothelial growth factor using trastuzumab and bevacizumab as first-line treatment of HER2-amplified breast cancer. Breast Cancer Res. Treat. 100(Suppl. 1) 310A (2006).
41. st Annual San Antonio Breast Cancer Symposium 2008. San Antonio, TX, USA, 10–14 December 2008.